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Abstract 
Postpartum thyroiditis (PPT) is a triphasic phenomenon that affects women who clinically are 
without thyroid disease prior to pregnancy but develop PPT in the first year postpartum or after a 
spontaneous/induced abortion (Vimalachandran, 2019). Recognition of thyroid dysfunction and 
possible differentials can augment the providers' ability to appropriately counsel and treat the 
patient. PPT affects about 5-10% of all women; of those that develop PPT, one in five patients 
will develop permanent hypothyroidism and require lifelong treatment (Burman, 2019). The 
etiology, risk factors, clinical course, prognosis, and treatment of PPT will be reviewed as it 
correlates with the clinical relevance of screening patients for potential thyroid dysfunction.  
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Postpartum Thyroiditis – Should Postpartum Mothers Be Routinely Screened for Thyroid 
Dysfunction Without Prior Indication of a Thyroid Condition?? 
Background 
Thyroid disorders are among the most common endocrine conditions evaluated and 
treated by clinicians during the antenatal and postnatal periods apart from diabetes (Tingi et al., 
2016). Postpartum thyroiditis is an autoimmune destruction of the thyroid gland, which is 
characterized by three (triphasic thyroid pattern) phases; thyrotoxic, hypothyroid, and a 
euthyroid phase (Pearce, 2015). Physiological changes of the thyroid along with pathological 
function are most affected during the antenatal period and the year following parturition resulting 
in a combination of increased metabolic demand, often causing an onset, exacerbation, or relapse 
of autoimmune diseases (Tingi et al., 2016). Postpartum thyroiditis does not always manifest 
clinically, indicating the importance of identification of this differential by the clinician (Gibson 
& Nelson-Piercy, 2018).   
During a healthy pregnancy, the thyroid increases in size and vascularity, the thyroid-
stimulating hormone reaches the upper limit of normalcy and decreases while the thyroxine (T4) 
and the triiodothyronine (T3) increases by fifty percent (Grossman & Porth, 2014). The increases 
in T3 and T4 are needed to maintain free thyroxine (fT4) within normal limits as pregnancy 
increases thyroxine-binding globulin giving women a high reserve within the thyroid gland 
(Grossman & Porth, 2014). Pregnancy is described as a "biological stress test" by 
endocrinologists, and without underlying conditions, the thyroid can compensate "flawlessly" 
(Stagnaro-Green et al., 2019). However, thyroid dysfunction antenatal and postnatal is associated 
with adverse outcomes for both the mother or baby, including anemia, miscarriage, fetal growth 
restriction, gestational diabetes, pre-eclampsia/gestational hypertension, pre-term birth/delivery, 
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neurodevelopmental delay, stillbirth, respiratory distress and fetal death (Gibson & Nelson-
Piercy, 2018; Nguyen & Mestman, 2019; Stagnaro-Green et al., 2019; Yalamanchi & Cooper, 
2015)   
Pearce (2015) and Vimalachandran (2019) have found that in PPT lymphocytic 
inflammation of the thyroid initially leads to a transient thyrotoxicosis which can last two to four 
months up to six to nine weeks; symptoms are typically mild and go unnoticed because the 
patient is adapting to other physiological changes in the postpartum period with a newborn/baby. 
If screened during this time, the T4 can have marked elevation in comparison to T3, and as these 
thyroid stores deplete a progression through a euthyroid to hypothyroid phase before thyroid 
recovery can occur. One-third of patients will experience the triphasic pattern, and one third can 
experience a biphasic pattern with either a thyrotoxicosis or hypothyroidism. The reoccurrence 
of PTT has been documented in nearly 70% of diagnosed patients.   
Screening for thyroid dysfunction is not routine antenatal, nor postnatal, and is typically 
only completed by targeted screening secondary to the patients' risk factors. The goal of this 
review is to determine if standardizing routine screening can prevent postpartum mothers from 
developing permanent hypothyroidism if screened, diagnosed, and treated within an appropriate 
timeframe. Clinical indication for an appropriate postpartum thyroiditis versus hypothyroidism 
differential diagnosis is essential due to their potential for different clinical courses and 
treatments. 
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Case Report 
Elizabeth was a 37-year-old patient that presented to the clinic for evaluation of ongoing 
fatigue, dry skin, weight gain of 15lbs., and difficulty with memory and concentration. The 
patient stated she noticed symptom onset three months prior initially with her weight gain, and 
fatigue. The patient did not have any recent changes in her typical day, attended a local gym but 
resorted to the sauna due to decreased endurance, and unusual exhaustion. During assessment, 
Elizabeth revealed an ongoing inability to stay on task for long periods. She denied any change 
in sleep or intake patterns but had been having difficulty passing bowels; denied any OTC 
intervention but had increased her water, fruits, and vegetable intake. The patient did have a 
primary care provider, which she presented to only when needed, which she contacted before 
presenting and had pre-ordered fasting labs completed.   
The patient was a G3P3 that was currently breastfeeding - her youngest child was born 
nine months ago without complication – her menses are irregular, she contributes this to 
breastfeeding, natural family planning with unknown last menstrual cycle. Besides the recent 
onset of stated symptoms patient had unremarkable health history, all health maintenance and 
immunizations were up to date, no known food, seasonal or drug allergies, and she was only 
taking two over the counter medications; a women's multivitamin, and a generic probiotic.    
Her physical examination revealed a well-developed and nourished woman, vitals, 
130/80 blood pressure, 76 pulse, 16 respiration, 100% on room air, 97.8 tympanic temperature, 
71 inches in height, and 81 kilograms in weight. No evidence of thyroid enlargement, tenderness, 
nodules or lymphadenopathy, cardiac assessment revealed regular rate and rhythm, no jugular 
venous distention, and clear lung sounds bilaterally, normoactive bowel sounds in all four 
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quadrants, soft, non-tender, with no masses. The patient did have generalized xerosis cutis; her 
affect mildly flat with some forgetfulness, memory, and judgment were appropriate for age. 
Elizabeth's diagnostic exam revealed an unremarkable complete blood count (CBC), 
comprehensive metabolic panel (CMP), glycated hemoglobin test (HgA1C) of 5.4%, vitamin D 
of 40ng/mL, negative urinalysis, human chorionic gonadotropin (hCG), C-reactive protein (CRP) 
of 4.0mg/L and a marked elevation of her thyroid-stimulating hormone (TSH) of 7.0mU/L and a 
decrease in thyroxine (T4) at 0.25mcg/dL. 
Based on Elizabeth's presentation of symptoms, her history, physical exam, and 
diagnostic findings, hypothyroidism was suspected. Per Naidu et al. (2019), it is not uncommon 
for patients to present with complaints of chronic fatigue, slowed thinking, constipation, dry 
skin, menstrual disturbances, and a modest weight gain with primary hypothyroidism. Physical 
exam usually reveals dry, coarse, or thickened skin, hair loss, or brittle hair, coarsening of voice, 
goiter, periorbital puffiness, swelling of hands, and feet, bradycardia, reduced systolic blood 
pressure, or increased diastolic blood pressure and delayed deep tendon reflexes. Diagnostic test 
results for hypothyroidism include an elevated TSH, a decreased serum free T4. 
However, because Elizabeth was nine months postpartum, she also had clinical suspicion 
for the triphasic thyroid hormone pattern of postpartum thyroiditis (PPT). Clinical presentation 
of PPT can vary, and because the patient did not have any risk factors before indicating the need 
for thyroid function screening antenatal nor postnatal, a thyroid peroxidase (TPO) antibody titer 
was added on to her previously collected labs. With the treatment guidelines/indications being 
similar for primary hypothyroidism and symptomatic postpartum thyroiditis the patient was 
treated with 25mcg of daily Levothyroxine and directed to return for follow-up in four to six 
weeks for a recheck on her TSH and T4 and potential increase of her medication until a 
8 
  
 
   
 
therapeutic index is reached or she can discontinue medication therapy (Naidu et al., 2019; 
Vimalachandran, 2019). Levothyroxine excretion, while breastfeeding reviewed with the patient 
and not contraindicated (Hale & Rowe, 2019). 
Literature Review 
 Research was conducted through the University of North Dakota's School of 
Medicine & Health Sciences Library, with primary search through Clinical Key, PubMed, and 
CINAHL. Postpartum thyroiditis and hypothyroidism were used with identified MeSH 
subheadings, complications, diagnosis, drug therapy, epidemiology, immunology, mortality, 
prevention and control, pharmacokinetics, pharmacology, statistics, and numerical data, and 
trends. Descriptors included English, female adults (age 19-44), publication within the past five 
years in the form of – Systematic Reviews, Meta-analysis, Practice Guidelines, Case Reports, 
Literature, and Narrative Reviews. Limitations yielded near 300 results; factors requiring 
removal included non-topic correlation, no abstract, no full-text availability, professional reply 
excerpts, duplication, and exceptional circumstance and consideration of interlibrary loan 
unavailability. Fifteen articles were identified with relevancy for this review. 
In order to avoid adverse maternal and fetal outcomes, early diagnosis and management 
of thyroid disruption, both antenatal and postnatal is vital. Due to the wide range of physiological 
changes that are experienced during pregnancy with the thyroid gland and hormones, diagnosis 
can often be challenging for the clinician. Clinical symptom presentation for postpartum 
thyroiditis can vary depending on the course of phase in dysfunction; symptoms of the 
hyperthyroid phase are often described as mild with generalized complaints of fatigue, 
palpitations, irritability, sleep disturbance, increased sweating, and heat intolerance (Kellerman, 
2020; Nguyen & Mestman, 2019; Vimalachandran, 2019). Within the hypothyroid phase patients 
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typically can present with complaints of constipation, irregular menstrual bleeding, impaired 
memory, or concentrations, fatigue, generalized aches, and pains, weakness, dry skin, hair loss, 
cold intolerance, difficulty with weight loss, or mild weight gain (Kellerman, 2020; Nguyen & 
Mestman, 2019; Vimalachandran, 2019). The etiology with thyroid dysfunction and postpartum 
depression remains unclear; however, patients with postpartum depression are recommended to 
be screened for a thyroid disorder (Iwen & Lehnert, 2018). Postpartum thyroiditis can impact 
milk letdown and the mother's ability to breastfeed successfully; women that demonstrate poor 
lactation should also be evaluated for thyroid disorders (Nguyen & Mestman, 2019). 
The physical exam of PPT is similar to those that occur in nonpregnant patients and is 
dependent on the phase in which the woman is presenting; examination of the thyroid may reveal 
a diffusely enlarged painless gland with a pebbly like texture, a painless small nontender firm 
goiter, or the thyroid gland can be normal without any palpable masses (Kellerman, 2020; 
Vimalachandran, 2019). Signs of hyperthyroidism may reveal hyperreflexia, tachycardia, with or 
without atrial fibrillation; a hypothyroid presentation may include delayed reflexes, nonpitting 
edema, dry skin, coarse/thickened skin, reduced systolic blood pressure, increased diastolic 
blood pressure, and bradycardia, or the patient could have a benign exam and present without 
any signs or symptoms suggestive of a thyroid disorder (Kellerman, 2020; Naidu et al., 2019; 
Vimalachandran, 2019). Distinguishing differences in hyper/hypothyroidism from healthy 
physiological changes in pregnancy and the postpartum period can be difficult; however, features 
suggestive of thyroid disorders that preceded pregnancy indicate a need for screening (Gibson & 
Nelson-Piercy, 2018). 
Due to the complexity of trimester-specific reference ranges for testing of thyroid 
function, this report only reflects postpartum screening and an antibody predictor of PPT within 
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the first trimester with normal reference ranges. Interpretation of diagnostic laboratory testing for 
hypothyroidism usually includes an elevated TSH and decreased serum free T4, with an anti-
TPO antibody positivity marker being the best predictor of PPT (Vimalachandran, 2019). 
However, the screening of asymptomatic antenatal and postnatal women for thyroid disruption 
remains controversial and not routinely recommended allowing variation in diagnosing and 
management practices. 
Guidelines & Recommendations 
Current guideline trends gathered within the literature presume a targeted screening 
approach rather than a universal approach that identifies women that are at high risk for 
developing thyroid dysfunction during pregnancy or in the postnatal period. Targeted screening 
is guided on three principles per Stagnaro-Green et al., (2019), risk factors identify patients that 
are predisposed to the disease of interest, screening individuals with those risk factors can help 
identify a majority of patients with a lower cost derived with targeted screening versus the 
downside of false positives and negatives. Kellerman (2019) and Mcdermott (2019) also found 
that the debate on universal screening varies from society to society with substantial opinion 
consideration from endocrinologists, obstetricians, gynecologists, and governmental agencies; 
however, targeted screening for predisposed patients all trend in similarity.  
The American College of Obstetricians and Gynecologists (ACOG) recommendations 
require testing of high-risk women that are symptomatic or have a personal history of any 
autoimmune diseases (Yalamanchi & Cooper, 2015). The Endocrine Society supports a "case-
finding" approach in conjunction with generalized guidelines across clinical resources such as 
up-to-date and 5minute consult which includes: patients that live in areas of moderate to severe 
iodine insufficiency, symptomatic, familial, or personal history of thyroid disease, or have any of 
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the following: thyroid peroxidase (TPO) antibodies, goiter, >30 years of age, diabetes, head, or 
neck irradiation, recurrent miscarriages, preterm deliveries, two, or more pregnancies, obesity, 
infertility, prior thyroid surgery (Burman, 2019; Donnay Candil, 2015; Naidu, 2019; Ross, 2020; 
Smith et al., 2017 Vimalachandran, 2010; Yalamanchi & Cooper, 2015). The American Thyroid 
Association (ATA) recommendations are similar of the Endocrine Society and clinical references 
with the addition that patients who have received recent administration of iodinated radiologic 
contrast agents or are currently prescribed amiodarone or lithium receive screening for thyroid 
dysfunction in the first trimester (Yalamanchi & Cooper, 2015). 
Studies have shown that a targeted screening and case finding approach may fail to 
identify near 30-80% of thyroid dysfunction in the antenatal and postnatal periods (Pearce, 2015; 
Smith et al., 2017). Nevertheless, a unanimous consensus remains about testing asymptomatic 
non-at-risk patients, with interest, however, regarding their availability, reliability, and potential 
for cost-effectiveness versus not testing patients. The recommendation for screening of thyroid 
dysfunction in high-risk patients should be completed in the first trimester with a thyroid 
peroxidase antibody (TPO-Ab) titer. The TBO can detect inflammation of the thyroid gland and 
can also predict dysfunction, autoimmune disorder(s), and other non-organ-specific antibodies, 
which can precipitate adverse pregnancy complications (Borba et al., 2019; Pearce, 2015). Per 
Vimalachandran (2019), TBO-Ab+ is the most predictive marker for PPT; women known to 
have the presence of antibodies within the first trimester should have their thyroid-stimulating 
hormone (TSH) measured at six to twelve weeks' gestation and repeated at six months 
postpartum or as clinically indicated. Women with positive antibodies usually have 
hypothyroidism between three to eight months postpartum, with 80% of them spontaneously 
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resolving at one year postpartum. However, of those that do not resolve 30-50% of them can 
develop permanent hypothyroidism within ten years. 
Detection 
Though there are not universal screening guidelines for asymptomatic antenatal and 
postnatal women, LeFevre (2015) discusses the theory of the pros and cons of detection and why 
they need to be considered. The benefits of early detection, like many conditions, may be 
beneficial for long term morbidity and mortality from permanent hypothyroidism, cancers, 
and/or cardiovascular diseases. The U.S Preventive Services Task Force (USPSTF) has found 
inadequacies in screening asymptomatic women for thyroid dysfunction in correlation to 
beneficial cardiovascular disease outcomes; however, they concluded early detection and 
treatment does not have clinically meaningful improvements in blood pressure, body mass index 
(BMI), bone density, lipid levels, or cognitive function. Harms of early detection included false-
positive results, psychological effects of patient labeling/diagnosing, over-diagnosing, 
overtreating, and being wrongly treated by inexperienced clinicians added Stagnaro-Green et al., 
(2019). Harmful impact of late detection can cause a multitude of complications including 
persistent hypothyroidism, congenital disabilities, goiter, cardiac issues, infertility, and 
myxedema (Burman, 2020). 
Special considerations 
Factors that can influence a patients’ TSH results include timing, prescribed medications, 
over-the-counter supplements, and their current state of health. In times of illness, during 
pregnancy, and in the postpartum period or when a patient may have other comorbidities such as 
protein malnutrition, hepatic failure, or nephrotic syndrome evaluation of thyroxine T4 and 
triiodothyronine T3 would be indicated (Naidu et al., 2019; Nguyen & Mestman, 2019). The 
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thyroid-stimulating hormone is in a state of constant fluctuation,  proving that it is not the best 
lone indicator of overall thyroid function in the postpartum period; once a patient reaches the 
hypothyroid state during PPT, there is a marked decrease in the T4 and T3 (Burman, 2019; 
Naidu, 2019; Paulson, 2019; Ross, 2020; Vimalachandran, 2010; Yalamanchi & Cooper, 2015). 
Nguyen and Mestman (2019) also stated that when a TPO-Ab+ is positive, the thyroglobulin 
antibody (TG-Ab) may also be positive; however, it is not a typical diagnostic marker of PPT. 
Lastly, in the postpartum period, thyroid hormone autoantibodies (TH-Ab) can interfere with 
appropriate evaluation of thyroid function due to their elevated concentrations and binding 
properties but resolve by 48 weeks postpartum. No reports have concluded their prediction of 
PPT. 
Nyugen and Mestman (2019) concluded that studies evaluating the prevention of PPT 
have been unsuccessful and have not been able to prove a reduction of risk in developing 
permanent hypothyroidism if diagnosed and treated early augmenting nonuniversal routine 
screening guidelines. Hypothyroidism has been reported in 2-21% of patients one year 
postpartum with reports up to 54%. Thirty to fifty percent of women that had PPT reported a 
diagnosis of permanent hypothyroidism as early as three years post-delivery, up to 12 years. 
Evaluation 
Due to the complexity of evaluating thyroid function in the postpartum period and non-
universal screening guidelines, Paulson (2019) describes a common discussion across the 
literature to not treat pharmacologically based on one set of diagnostic results if the patient is 
asymptomatic because of the transient prediction of returning to euthyroid state and the 
sensitivity and specificity of TSH levels. Recommendation to repeat a TSH, or fT4 is based on 
slight deviation out of reference range which should be completed at the same laboratory; please 
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note diagnosing hypothyroidism and evaluating TSH levels to assess replacement therapy are not 
included in this literature and do not reflect the prior statements (Paulson, 2019). However, the 
USPSTF states that TSH is the gold standard for detecting thyroid dysfunction and that it should 
be performed at three to six-month intervals to rule out or confirm abnormal findings (LeFevre, 
2015). Optimal screening intervals and frequencies are unknown. 
Another statement that should be taken into consideration by Tandeter and Fraenkel 
(2018) indicates that once a patient is pharmaceutical, they are always pharmaceutical; with 
clinical guidelines to start therapies, there are not always clear cut guidelines to discontinue 
therapy once a therapeutic index is reached. The literature shines a light on the recent publication 
of medications that should or could be stopped, such as antihypertensives and statins. However, 
in patients with any variation of hypothyroidism, these patients usually receive lifelong therapies 
despite the restoration of thyroid function. Variances within the literature describe select few 
patients that are treated with levothyroxine and have been able to titrate off the medication once 
a euthyroid level is reached – variations of patients include deficiency in vitamin d, iodine uptake 
and other autoimmune disorders respectfully (Burman, 2019; Naidu, 2019; Paulson, 2019; Ross, 
2020; Vimalachandran, 2010; Yalamanchi & Cooper, 2015). 
Treatment 
Approaching the patient with PPT is primarily based on the clinicians' index of suspicion 
for hypothyroidism and correlation with clinical symptoms, physical examination, and laboratory 
values. Levothyroxine is the principle monotherapy treatment for hypothyroidism but is 
dependent on different factors. Asymptomatic patients with mild thyroid function test 
abnormalities do not require pharmacological therapy; however, they should have their TSH and 
free T4 monitored for evaluation of resolution, or to detect permanent hypothyroidism (Burman, 
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2019). Symptomatic hypothyroidism or a TSH above 10mU/L requires T4 replacement; 
dependent on the degree of elevation determines the appropriate dose of Levothyroxine 
(Burman, 2019). 
The prediction of permanent hypothyroidism is inefficacious; therefore, patients are 
titrated off at 12 months postpartum for a reevaluation of spontaneous resolution of their thyroid 
function, those that do not have spontaneous resolution of thyroid function require therapy and 
annual evaluations' of TSH as indicated (Burman, 2019; Gibson & Nelson-Piercy, 2018; Pearce, 
2015; Vimalachandran, 2019). Patients that desire future pregnancies should receive education 
and the recommendation to continue T4 supplementation along with breastfeeding women 
(Nguyen & Mestman, 2019).  
Conclusion 
Throughout the literature, the question remains, should we be screening non-at-risk 
postpartum mothers for thyroid dysfunction? There seems to be insufficient data supporting the 
recommendation for routine screening in asymptomatic patients that are not predisposed to 
thyroid disorders. In the absence of strong evidence indicating a need for universal routine 
screening, the decision to screen, treat, and manage this condition lies primarily on an 
appropriate history and physical by the clinician. Mandated screening does not exist; however, 
recommended screening of thyroid function does occur when patients reach certain ages' 
dependent on the guidelines a clinician chooses to follow (Naidu et al., 2019). The literature on 
screening asymptomatic patients for thyroid dysfunction was partially scarce, though the clinical 
question prompts an appropriate differential diagnosis consideration when treating women of 
childbearing age. 
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Learning Points 
• Understanding the physiological changes and pathological function of the thyroid and its 
dysfunction that a patient may encompass during pregnancy is vital for the best maternal 
and fetal outcomes.  
• Though there is conflicting research on the indication for routine screening of postpartum 
mothers, the clinician must be able to identify this differential within the practice setting 
when working with antenatal and postnatal women.  
• If a clinician chooses to routinely screen patients within their practice setting, the patient 
should be informed and fully aware of the potential clinical benefits and harms of 
screening within the antenatal and postnatal periods.  
• If the clinician chooses to screen asymptomatic postnatal women, be confident in the 
clinical decision to treat or not treat. (If you screen, know why you are screening, and 
what you are going to do about it).  
• Currently, no known interventions exist to prevent hypothyroidism (Kellerman, 2019). 
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